Dr. Jennifer Bath, CEO & President of ImmunoPrecise Antibodies Ltd., was recently interviewed by Benzinga.
ImmunoPrecise is a biotherapeutic research company and is a leader in antibody discovery services, utilizing complex artificial intelligence technologies. The company integrates cutting-edge tech and AI in its propriety platform, LENSai.
The revolutionary technology pools together data and disparate knowledge across scientific literature – knowledge that may have been previously siloed – to make insights that would not be possible otherwise.
